Trials / Completed
CompletedNCT03351166
A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects
A Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Dialysis Subjects With Renal Anemia Who Are Not Treated With Erythropoiesis-Stimulating Agents (ESAs)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Molidustat in dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Molidustat (BAY85-3934) | Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response |
Timeline
- Start date
- 2018-01-22
- Primary completion
- 2018-10-23
- Completion
- 2018-11-20
- First posted
- 2017-11-22
- Last updated
- 2021-01-29
Locations
20 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03351166. Inclusion in this directory is not an endorsement.